This trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
1 Primary · 6 Secondary · Reporting Duration: Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years
1450 Total Participants · 3 Treatment Groups
Primary Treatment: Bortezomib · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Did not meet criteria||50.0%|